Hematology and Medical Oncology Fellowship

About the Program

The Fellowship Program of the Division of Hematology, Oncology and Blood & Marrow Transplantation welcomed its first fellow in 1971 and currently invites 4 fellows to join the program each year. Graduates of our program have pursued successful careers as: academicians in basic and clinical research, in community oncology, in medical education, and in the pharmaceutical industry.

We invite you to consider the advantages of a program with:

  • A curriculum differentiated to meet your career goals
  • Comprehensive exposure to all subspecialties of Hematology and Oncology
  • Opportunities to participate in basic and laboratory research at a Big-Ten University
  • Small-town life with big-city culture

We invite you to join the ranks of our graduates who have found success in the full range of careers available in Hematology and Oncology.

Our Mission

The mission of the University of Iowa Hematology and Oncology fellowship program is to develop outstanding clinicians who will be future leaders in hematology and oncology. As the state of Iowa's only tertiary care referral center, we serve both our local community and the entire state through care of patients with hematologic or oncologic diagnoses. Our purpose is to develop fellows who can serve as future clinicians for the community in the State of Iowa, as well as future leaders in research in hematology and oncology here at the University of Iowa and elsewhere who will promote improved health through the development of innovative research and improved clinical care. The mission of our fellowship program aligns closely with the mission of the University of Iowa Health Care which is to promote discovery, innovative education and excellent patient care for the people of the State of Iowa.

We Aim to:

  1. Train hematologists and oncologists who are experts in the science of hematology and oncology, responsive to the psychosocial needs of patients with cancer and blood disorders, and sensitive to the impact of socioeconomic factors that can impact delivery of care and quality of life.
  2. Support fellows in the development of their individual career.  This starts with helping the fellow discern their career path, tailoring the educational curriculum to meet their individual educational needs, and supporting the fellow with mentorship to guide them through their fellowship training.
  3. Train physicians who have developed the skills of resilience and self-care to enable them to have a long, healthy and productive career.

Educational Environment

Clinical training in Hematology, Oncology and Blood and Marrow Transplantation occurs within the Holden Comprehensive Cancer Center at University of Iowa Hospitals & Clinics and at the Veteran’s Administration Medical Center, Iowa City. All faculty are members of the Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine in the Carver College of Medicine.

The ambulatory Clinical Cancer Center within the Holden Center is organized in disease or site-specific multidisciplinary teams. Fellows are part of the multidisciplinary team and interact not only with their supervising faculty member, but also with oncology specialists in surgery, radiation oncology or a medicine sub-specialist in the clinic.  In addition, fellows can participate in one of more than a dozen disease-specific Tumor Boards.

Physical Environment

The Holden Comprehensive Cancer Center at The University of Iowa coordinates all cancer-related research, education, and patient care throughout the University of Iowa by faculty from 38 departments in six colleges, as well as UI Hospitals & Clinics. Founded in 1980, Holden Cancer Center includes patient care areas such as:

  • The John and Mary Pappajohn Clinical Cancer Center, located on the first and second floors of the Pomerantz Pavilion of UI Hospitals & Clinics.
  • Adult Blood and Marrow Transplantation – our Bone Marrow Transplant Service is very active;  in 2020 our center performed 163 adult auto-transplants, allo-transplants and CAR-T procedures.
  • The Radiation Oncology Center of Excellence is located in the lower level of the Pomerantz Pavilion of UI Hospitals & clinics.

The Holden Comprehensive Cancer Center is an NCI-designated Comprehensive Cancer Center.  We received this designation in 2000.  The Holden Comprehensive Cancer Center received its fourth 5-year renewal from the NCI in 2021.

Research is conducted in laboratories throughout the University of Iowa campus. The Roland and Ruby Holden Cancer Research Laboratories, part of the Medical Education and Research Facility, allow the Cancer Center to integrate many researchers in close proximity to each other.

The University of Iowa Hospitals & Clinics is the designated tertiary care hospital for the state of Iowa and is the nation's largest university-owned teaching hospital, with 50,000 patient admissions and 800,000 outpatient visits annually. Patients with neoplastic diseases are referred to The University of Iowa from a referral area that includes Iowa and its neighboring states. This referral base and the variety of patients seen have been remarkably stable despite recent changes in health care delivery systems.

The Iowa City Veteran’s Administration Medical Center  is conveniently located adjacent to UI Hospitals & Clinics.  The Iowa City VA Hospital Hematology Oncology Program is staffed by faculty from the University of Iowa.  Facilities include a clinic, an infusion area, and a clinic conference room.  The service is very busy and has clinics 5 days per week.

The University of Iowa was founded in 1847 and has a total enrollment of 32,150 students. The College of Medicine has over 600 medical students, 180 allied health students, 700 faculty, 1900 support staff, and more than 550 residents and fellows. The research enterprise of the UI Carver College of Medicine (CCOM) garnered $245 million in external funding in 2020 and the UI ranks 16th among public institutions in NIH funding. The Hardin Library for the Health Sciences, which is located between the University and VA Hospitals, houses 213,000 volumes, 2,700 periodicals, and 80 on-line databases in a modern 60,000-square-foot building.

Typical Rotation Schedule

Year 1:

  • Hematology Consult Service, UI Hospitals & Clinics – 8 weeks
  • Oncology Consult Service, UI Hospitals & Clinics -- 8 weeks
  • VA Consult Service, VA – 4 weeks
  • Bone Marrow Transplant clinic – 4 weeks
  • Bone Marrow Transplant – 4 weeks
  • Malignant Hematology – 4 weeks
  • Supportive Oncology – 4 weeks
  • Ambulatory Clinics – 12 weeks
  • Research – 4 weeks (for fellows on the Clinical Investigator Pathway or Physician Scientist Pathway.  This allows the fellow time to work with their mentor(s) to develop their project concept so they are ready to start their research as soon as their clinical rotations are completed in year 2).

Year 2:

  • Hematopathology – 4 weeks
  • Transfusion Medicine – 4 weeks
  • Gynecologic Oncology – 4 weeks
  • Hematology Consult Service – 4 weeks
  • Oncology Consult Service – 4 weeks
  • Malignant Hematology - 4 weeks
  • Additional clinical electives, dedicated research time/coursework, subspecialty ambulatory clinics. This will vary depending upon the fellow’s Career Pathway.

Year 3:

  • Inpatient Hematology/Oncology service – 4 weeks
  • Hematology Consult Service – 4 weeks
  • Oncology Consult Service – 4 weeks
  • Additional clinical electives, dedicated research time/coursework, subspecialty ambulatory clinics. This will vary depending upon the fellow’s Career Pathway.

Fellows Conferences

Hematology/Oncology Core Conference:
The Core Conference Series features 45-minute lectures on major topics in hematology and oncology.  This series follows the topic outline provided for fellow education by the American Society of Hematology and the American Society of Clinical Oncology. The lectures are provided by faculty of the Division of Hematology/Oncology or guest speakers from other departments who are experts in that topic.   This conference occurs twice weekly, Tuesday and Friday at 8 am. 

Fellows Conference:
This conference may take one of several forms:

  • Journal Club, in which a peer-reviewed article on emerging or controversial topics in hematology oncology is reviewed;
  • Patient Management Conference at which difficult patient-management problems encountered by the fellow in clinic or in the hospital are presented. The patient-management conference may include discussion of the literature pertinent to the case being discussed.
  • Morbidity and Mortality Conference
  • Board Preparation session
  • General Topic Review

This conference occurs weekly (Wednesday at 8 am)

Blood Club:
This case-management conference covers management and clinical topics in benign and malignant hematology encountered in recent patients at University of Iowa Hospitals & Clinics or Veterans Administration Hospital. This is a multidisciplinary conference with attendance by faculty from adult and pediatric Hematology/Oncology, Hematopathology and Blood Bank. The conference is moderated by Dr. Usha Perepu of the Division of Hematology/Oncology.    This conference occurs weekly (Thursday at 8 am).

Cancer Center Grand Rounds:
This is a multidisciplinary conference involving all members of the cancer center (medical oncology, radiation oncology, surgical oncology and basic sciences). Presentations may focus on basic science related to oncology, advances in translational medicine, or state-of-the-art clinical care reviews.  Grand Rounds occurs weekly (Friday at Noon).

Lymphoma Conference:
Lymphoma conference is a clinical case-management conference at which patients with newly-diagnosed lymphoma or difficult lymphoma case management problems are discussed. This is a multi-disciplinary conference with participating faculty from the Division of Hematology/Oncology, Pathology and Radiology. The conference is moderated by Hematology/Oncology division member Dr. Brian Link.  This conference occurs weekly (Monday at noon).

Interdisciplinary Fellowship Conference

Below is an example of the Department of Internal Medicine Common Curriculum Schedule. It is shared between Fellows from all divisions of the Department.

PDF icon20-21 Fellows Conference Master Schedule.pdf

Research Training

Research or other scholarly activity is an important component of fellowship education. However, the type of scholarly activity will vary depending upon the career interests of the fellow. During the first year, each fellow meets with a mentorship committee composed of members of the Division of Hematology and Oncology. The committee works with the fellow to help the fellow discern her or his career goals. By the end of the first year, fellows will determine the training track they will pursue (Master Clinician, Clinical Investigator, Medical Educator, Physician Scientist). The goal is to align the scholarly activity with the career goal of the fellow.

The research mentor is not limited to a member of the division, and can be an investigator in another department of the University of Iowa (for example, the School of Public Health for those interested in outcomes research, a basic science department such as Immunology, Pharmacology or Biochemistry for those interested in basic research, or in OCRME for those interested in medical education, to name just a few).

Fellows are actively encouraged to submit abstracts and papers based upon their research. We are committed to supporting our fellows’ research activities and funding is available to support travel costs to allow fellows to present their research at national scientific and academic meetings. In the past year our fellows have attended multiple meetings including: ASCO Annual Meeting, ASH Annual Meeting, ASCO-GU, ASCO-FDA Fellows’ day, Society of Neuro-Oncology Annual Meeting, Tandem Transplant Meeting, ASCO-SITC Clinical Immuno-Oncology Symposium, AACR Special Conference on Advances in Sarcomas and the Iowa Oncology Society Annual Meeting.

Recent Scholarly Activity

Iowa Oncology Society 2020 Poster Competition Winners
As part of its Outstanding Hematology/Oncology Fellow and Resident Recognition Competition, the Iowa Oncology Society is pleased to share the research findings of its 2020 winning poster presentations.


Class of 2019

Najla Itani, MD

Publications

  • Itani N, Grogan, N, Mott, S, Phadke, S. Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association with Survival. Clin Breast Cancer 2019 Nov 21. PMID: 32007466
  • Phadke, S, Vander Weg M, Itani N, Grogan N, Ginader T, Mott S, McDowell B. Breast Cancer Patient Preferences for Test Result Communication. Breast J 2019 Nov; 25(6)1326-1327. PMID 31297915

Umang Swami, MBBS

Abstract & Presentations

  • Swami U., Monga V., Tanas M., Bossler A., Mott S., Smith B., Milhem M. A pilot study targeting angiogenesis using bevacizumab combined with gemcitabine/docetaxel and valproic acid (VPA), a histone deacetylase inhibitor (HDACi) in advanced soft tissue sarcomas (STS). Presented at AACR Special Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; Philadelphia, PA. 05/18/2017.
  • Kam A.E., Chaudhary I., Ghalib M.H., Shah U.H., Swami U., Kuo D.Y.S., Hwang C., Elrafei T.N., Cohen B., Gartrell B.A., Kaledzi E., Chuy J.W., Cheng H., Rajdev L., Haigentz M. Jr., Mani S., Goel S. . Risks and benefits of phase I trials: Eighteen-year experience from a single institution. Presented at American Society of Clinical Oncology Annual Meeting; Chicago, IL. 06/02/2017.
  • Clinical trials: Pembro in Melanoma. Discussion Session I (Cancer Immunotherapy). Presented at: Cancer Epidemiology and Population Sciences-Cancer Genes and Pathways Program Retreat. 03/07/2018.
  • Experience with BRAF and MEK inhibitors after immunotherapy in metastatic melanoma. Presented at Iowa Oncology Society, 2018 Spring Conference; West Des Moines, IA. 04/13/2018.
  • Swami U., Monga V., Knutson T., Bossler A., Zakharia Y., Milhem M. Prognostic markers for progression free survival (PFS) to anti PD-1 therapies in metastatic melanoma. Presented at Annual Meeting; 06/01/2018.
  • Swami U., Monga V., Zakhraia Y., Milhem M. Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series. J Clin Oncol 35, 2017 (suppl 7S; abstract 123) Presented at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, Orlando, FL.
  • Swami U., Monga V., Tanas M., Bossler A., Mott S., Smith B., Milhem M. A pilot study targeting angiogenesis using bevacizumab combined with gemcitabine/docetaxel and valproic acid (VPA), a histone deacetylase inhibitor (HDACi) in advanced soft tissue sarcomas (STS). To be presented at AACR Special Conference on Advances in Sarcomas: From Basic Science to Clinical Translation. Thursday, May 18, 2017, Philadelphia, PA
  • Swami U. Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series. Presented at Iowa Oncology Society, 2017 Spring Conference, West Des Moines. April 7, 2017 

Publications

  • Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, Khan M, Frydenlund N, Srikantha R, Vanneste M, Henry M, Milhem M. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget. 201724; 8 (51) : 89182-89193.
  • Swami U, Monga V, Milhem M. Gastrointestinal stromal tumors-are we stuck and the way forward. Translational gastroenterology and hepatology. 2017; 2 : 93.
  • Monga V, Swami U, Tanas M, Bossler A, Mott SL, Smith BJ, Milhem M. A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. Cancers. 201817; 10 (2) : 53.
  • Swami U, Zakharia Y, Zhang J. Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. Journal of immunotherapy (Hagerstown, Md. : 1997). 201817; Epub ahead of print : Epub ahead of print.
  • Swami U, Lenert P, Furqan M, Abu Hejleh T, Clamon G, Zhang J. Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018; 13 (6) : e102-e103.
  • Swami U, Ma D, Zhang J. Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018; 13 (7) : e129-e130.
  • Kam A.E., Chaudhary I., Ghalib M.H., Shah U.H., Swami U., Kuo D.Y.S., Hwang C., Elrafei T.N., Cohen B., Gartrell B.A., Kaledzi E., Chuy J.W., Cheng H., Rajdev L., Haigentz M. Jr., Mani S., Goel S. Risks and benefits of phase I trials: Eighteen-year experience from a single institution. Accepted for publication in Conference Proceedings of 2017 ASCO Annual Meeting
  • Swami U, Shah U, Goel S. Eribulin in non-small cell lung cancer: challenges and potential strategies. Expert opinion on investigational drugs. 2017; 26 (4) : 495-508.
  • Zakharia Y.; Monga V.; Swami U.; Bossler A.D.; Freesmeier M.; Frees M.; Khan M.; Frydenlund N.; Srikantha R.; Vanneste M.; Henry M.; Milhem M. Targeting epigenetics for t  reatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase Ib study. Submitted to Clinical Epigenetics

Class of 2018

Andrew Iliff, MD

Publications

  • Iliff A, Divine C, Diaz F, Aljitawi O, Abhayankar S, McGuirk J, Ganguly S. Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine. Leukemia & lymphoma. 2016; 57 (5) : 1189-90.

Kalyan Nadiminti, MBBS

Publications

  • Nadiminti K, Leone JP. Intraocular bevacizumab in the treatment of choroidal metastases from breast cancer. BMJ Case Rep. 2016 Jul 18

Meredith Schaffner, DO

Abstracts & Presentations

  • Schaffner M, Bogadnich I, Smelser J, Zimmerman M, Perepu U. HIT or miss: improving the quality of diagnosing heparin-induced thrombocytopenia at an academic medical center.  Poster to be presented at: International Society of Thrombosis and Hemostasis Annual Congress, 12 July 2017.

Publications

  • Schaffner M, Rosenstein L, Ballas Z, and Suneja M. Significance of hyperferritinemia in hospitalized adults.  Accepted manuscript to the American Journal of Medical Sciences as of 24 April 2017. Expert opinion on investigational drugs. 2017; 26 (4) : 495-508.

Vyshak Alva Venur, MBBS

Abstracts & Presentations

  • Khanna R, Venur VA, Narechania S, Elson P, Daw H, Spiro TP, Haddad A. Prophylactic use of Granulocyte-colony stimulating factors (G-CSF) in cancer patients: Adherence to NCCN guidelines. Presented at 2016 ASCO: Quality Care Symposium; Phoenix, AZ. 02/27/2016.
     
  • Khanna R and Venur VA. Prophylactic use of Granulocyte-colony stimulating factors (G-CSF) in cancer patients: Adherence to NCCN guidelines. Presented at: Quality Improvement Symposium: Innovating for Quality, University of Iowa Hospitals and Clinics. 04/06/2016.

Book Chapters

  • Venur VA and Ahluwalia MS. Targeted Therapy in Brain Metastases: Ready for Primetime?. 2016 ASCO Educational Book. 2016; 1 : e123-130.
  • Berghoff AS, Venur VA, Preusser M, Ahluwalia MS. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. 2016 ASCO Educational Book. 2016; 35 : e116-22.
  • Kshettry VR, Yu JR, Venur VA, Ahluwalia MS, and Recinos PF. Comprehensive Management of Chordoma. In: Raghavan D, Blanke C, Reaman G, Kim E, Brown J, Sekeres M, Ahluwalia MS. Textbook of Uncommon Cancer. Wiley; 2017:847-855 .

Publications

  • Kotecha R, Miller J, Venur VA, Mohammadi AM, Chao ST, John H. Suh JH, Barnett GH, Murphy ES, Yu JS, Vogelbaum MA, Angelov L, Ahluwalia MS. Melanoma Brain Metastasis: The Impact of Stereotactic Radiosurgery, BRAF mutational. Submitted. 2016; Accepted for publication by Journal of Neurosurgery
  • Venur VA, Leone JP. Targeted Therapies for Brain Metastases from Breast Cancer. International journal of molecular sciences. 2016; 17 (9).
  • Shonka N, Venur VA, Ahluwalia MS. Targeted Treatment of Brain Metastases. Current neurology and neuroscience reports. 2017; 17 (4) : 37.
  • Venur VA, Joshi M, Nepple KG, Zakharia Y. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Design, Development and Therapy. 2017; 2017:11 : 1175-1182.
  • Venur VA, Funchain P, Kotecha R, Chao ST, Ahluwalia MS. Changing treatment paradigms for patients with brain metastases from melanoma. Accepted for publication by Oncology (Williston Park).

Class of 2017

Rohan Garje, MBBS

Abstracts & Presentations

  • Jaskirat Singh Randhawa, Sina Shafiei, Mykola Onyshchenko, Susmita Sakruti, Rohan Garje, Vyshak Alva Venur, Xuefei Jia, Timothy Peter Spiro, Abdo S. Haddad, Hamed Daw. Predictive factors for late (>5 years) distant recurrences in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients: >20-year follow-up. ASCO 2014; May 30 2014; Chicago, Illinois

Publications

  • An J, Garje R, Wanat KA, Leone JP. Dabigatran related leucocytoclastic vasculitis BMJ Case Rep. 2017 Jan 4;2017. pii: bcr2016217423. doi: 10.1136/bcr-2016-217423.
     

Book Chapter

  • Ahluwalia MS, Rohan Garje, Wen PY, Mehta M. Adjuvant Therapies (Chemotherapy and Radiation Therapy) for Atypical and Anaplastic Meningiomas. In: Dr. Alfredo Quiñones-Hinojosa and Shaan M. Raza. Controversies in Neuro-Oncology: Best Evidence Medicine for Brain Tumor Surgery. New York, NY: Thieme Medical Publishers, Inc.; 2013: 300. 

Ravi V. Patel, MD

Abstracts & Presentations

  • Muhammad Furqan, Muhammad Uzair Saqlain, Sarah L Mott, Ravi Patel, Douglas Earl Laux, Jun Zhang, Laith I. Abushahin, Carryn M. Anderson, John Watkins, Anthony N Snow, Wenqing Sun, Gerald H. Clamon. Retrospective comparison between high dose cisplatin & less intensive cisplatin/paclitaxel concurrently with radiation for locally advanced head and neck cancer (LAHNC). for ASCO Annual Meeting2016; June3-7 2016; Chicago, IL.

Grerk Sutamtewagul, MD

Abstracts & Presentations

  • Sutamtewagul G, Abbi KKS, Farooq U, Mott SL, Dozeman L, Silverman M. Non-Biologic Factors and Outcomes in Allogeneic Stem Cell Transplant. Presented at Iowa Oncology Society Meeting; Des Moines, IA. 04/15/2016.
  • Sutamtewagul G, Abbi KKS, Farooq U, Mott SL, Dozeman L, Silverman M. Busulfan and Fludarabine As Conditioning Regimen for Unrelated Allogeneic Stem Cell Transplant: A Single-Center Experience. Presented at BMT Tandem Meeting 2016; Honolulu, Hawaii. 02/22/2016.
  • Sutamtewagul G, Abbi KKS, Farooq U, Mott SL, Dozeman L, Silverman M. Non-Biologic Factors and Outcomes in Allogeneic Stem Cell Transplant. Presented at BMT Tandem Meeting 2016; Honolulu, Hawaii. 02/18/2016.
  • Sutamtewagul G, Abbi KKS, Farooq U, Mott SL, Dozeman L, Silverman M. Non-Biologic Factors and Outcomes in Allogeneic Stem Cell Transplant. Presented at BMT Tandem Meeting Sutamtewagul G, Laenvejkal P, Clamon G. Paraneoplastic Isaacs syndrome: a case report and review of literature. Journal of community and supportive oncology. 2016.

Publications

  • Sutamtewagul G, Laenvejkal P, Clamon G. Paraneoplastic Isaacs syndrome: a case report and review of literature. Journal of community and supportive oncology. 2016

Class of 2016

Varun Monga, MBBS

Abstracts & Presentations

  • Immunomodulation of pembrolizumab treated metastatic melanoma patients after progression with sequential temozolomide – U Swami, V Monga, Y Zakharia, M Milhem. Feb 2017 ASCO-SITC Clinical Immuno-Oncology Symposium Orlando, FL
  • Neoadjuvant Intralesional Injection of Talimogene Laherparepvec with Concurrent Preoperative Radiation in Patients with Locally Advanced Soft Tissue Sarcomas: Phase 1b/2 trial – V Monga, B Miller, S Bhatia, C Anderson, B Allen, S Bell, D Lubaroff, Z Balas,C Abanonu, M Milhem. Annual CTOS meeting, Lisbon, Portugal. Nov 2016
  • The impact of the presence of ductal carcinoma in situ in patients with invasive ductal carcinoma - L Xu, V Monga, A Thomas, J Leone. Poster at SABCS Dec 2016

Publications

  • Discrepancy in understanding of treatment goals in cancer patients. V Monga, H Kaleem, S Mott, A Button, G Zamba, M Milhem – J Clin Oncol 33, 2015 (suppl; abstr e20574)
  • Monga V, Leone JP. Metastatic Adenoid Cystic Carcinoma of the Breast. Breast J. 2016 Mar-Apr 22(2): 239-40. Doi: 10 1111/tbj. 12562 Epub 2015 Dec 19. No abstract available. PMID: 26684244
  • Monga V, Silverman M. Pulmonary extramedullary hematopoiesis involving the pulmonary artery. Hamatol Rep. 2015 Mar 24:7(1):5714. Doi: 10 4081/hr. 2015.5714 eCollection 2015 Feb 24. PMID:25852851

Sneha Phadke, D.O.

Publications

  • Phadke S, Thomas A. Targeting Cell Cycle Progression: CDK4/6 Inhibition in Breast Cancer. Contemporary Oncology. 2014; 6(4):6-11.
  • Raman R, Mott SL, Schroeder MC, Phadke S, El Masri J, Thomas A. Effect of Body Mass Index – and Actual Weight – Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.Clin Breast Cancer 2016 Dec: 16(6):480-486. Doi: 10 1016/j.clbc. 2016 06 008 Epub 2016 Jun 23 PMID: 27431461
  • Phadke S, Thomas A, Yang L, Moore C, Xia C, Schroeder MC. Frequency and Clinical Significance of Extramammary Finding on Breast Magnetic Resonance Imaging. Clin breast Cancer 2016 Oct: 16(5): 424-429. Doi: 10. 1016/j.clbc.2015 Aug 28. PMID: 26403074

Rachna Raman, MBBS

Publications

  • Raman R, Mott SL, Schroeder MC, Phadke S, El Masri J, Thomas A. Effect of Body Mass Index – and Actual Weight – Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.Clin Breast Cancer 2016 Dec: 16(6):480-486. Doi: 10 1016/j.clbc. 2016 06 008 Epub 2016 Jun 23 PMID: 27431461
  • Raman R, Deorah S, McDowell BD, Abu Hejleh T, Lynch CF, Gupta A. Changing incidence of esophageal cancer among white women: analysis of SEER data (1992-2010). Contemp Oncol (Pozn). 2015: 19(4):338-40 doi: 10.5114/wo.2015.54390 Epub 2015 Sep 28. PMID:26557784
  • Raman R, Vaena D. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int. 2015: 2015::367354. Doi: 10. 1155/2015/367354 Epub 2015Jun 16. Review PMID: 26161397
  • Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973 – 2003: a population-bases study. BJU Int. 2012 Mar:109(6):824-30. Doi: 10.1111/j. 1464-410X.2011.10523 .x. Epub 2011 Aug 23. PMID: 21883857

T32 in Hematology

Hematology T32 Training (T32 HL007344)

This NIH-funded training program in hematology that has been successful in attracting young scientists and physician-scientists into academic careers in hematology for over 40 years. The program has as its primary objective to prepare MD, MD/PhD, and PhD postdoctoral fellows for productive careers as academic scientists and physician-scientists. The focus of training supported by this grant remains within the core scientific discipline of hematology.

The training is carried out in an enriched environment of active basic, translational and clinical investigation at an institution that emphasizes the career development and collaborative science. The specific objectives are:

  1. To identify and recruit outstanding postdoctoral trainees, of diverse gender, ethnicity and culture, who wish to obtain comprehensive knowledge of the principles and techniques of basic and translational research related to hematology, blood cells, vascular biology, coagulation, hematopoiesis, and immunobiology;
  2. To attract highly motivated scientists and physician-scientists and provide them with comprehensive instruction in the design and implementation of high quality research projects, including participation in cross-disciplinary research teams;
  3. To train physician-scientists for academic careers in hematology and related scientific disciplines and prepare them for successful transition to independent investigators; and
  4. To expose talented PhD scientists to the field of hematology and train them for careers as independent investigators and research scientists.

The curriculum includes core lectures in clinical hematology and workshops in hematology research methods, rigor and reproducibility, and grant writing. Mentoring committees and individual development plans are required for all trainees. The foundation of training is centered on an individual mentored research project, marked by a period of intensive, sustained research under the guidance of an established, dedicated mentor.

This training is supplemented and enhanced by didactic and mentored training opportunities in team science and translational science, and by exposure to productive investigators working in related areas, including scientists with expertise in basic biomedical science, genomics, computational biology, and bioinformatics. The rich training environment provided by the diverse faculty, extensive laboratory, clinical, and core facilities, and strong institutional support should ensure continued success in attracting and preparing highly qualified postdoctoral trainees for careers in academic hematology.

Applications are being accepted for postdoctoral training positions on the NIH-funded T32 Hematology training grant (T32 HL07344) Program in Hematology: Molecular and Cell Biology of Blood Cells.

Post-doctoral Trainees (MD, PhD, or MD-PhD) interested in basic, translational or clinical research in the broad field of hematology, including 1) Hemostasis, thrombosis and vascular biology, or 2) hematopoiesis and immunobiology, are encouraged to apply. Applicants must be US Citizens or Permanent Residents.

To request application materials, please contact:

Steven R. Lentz, MD, PhD
Henry Hamilton Chair in Hematology
Director, Hematology Postdoctoral Training Program
steven-lentz@uiowa.edu

 

Career Tracks

Career opportunities in hematology and oncology are exceptionally diverse. To help prepare each individual fellow for this variety, we have developed four broad career tracks: Master Clinician Pathway; Clinical Investigator Pathway; Clinical Educator Pathway; and Physician Scientist Pathway. Each track, selected by each fellow in the first year, offers differentiated curriculum, shaped with a mentor’s guidance to meet individual educational and career goals.

Master Clinician Pathway

This track will prepare the fellow for leadership in a community hematology and oncology practice. This pathway provides the fellow with increased opportunities for clinical training. In addition, fellows will complete a policy project in collaboration with cancer center administration and various other quality improvement projects. 

Clinical Specialist Pathway

The goal of the Clinical Specialist track is to prepare the fellow for a career in academia with a focus on clinical investigation.  This curriculum track will prepare oncology fellows for an academic career as a subspecialist without the need for additional subspecialty training post medical oncology fellowship.

The 6 areas of focus for this track are:

  • Melanoma and Sarcoma
  • Lymphoma
  • Neuroendocrine tumors
  • GU Oncology
  • Phase 1 and Experimental Therapeutics
  • Immunotherapy

Oncology fellows in this track will have increased clinical exposure in their areas of specialization. This would include:

  • Two weekly subspecialty clinics in their area of focus during their third year
  • Presentation and participation in multidisciplinary tumor boards within their subspecialty on a weekly basis
  • Fellows may elect to rotate in additional specialty clinics to further develop expertise.  For example, fellows in the neuroendocrine tumor pathway would rotate through neuro-endocrinology clinic and nuclear medicine; fellows in the melanoma/sarcoma clinic may rotate within dermatology and/or melanoma surgery clinic; fellows specializing in lymphoma would have additional rotations in hematopathology; fellows in immunotherapy would rotate through multiple outpatient clinics that have a focus on immunotherapy (for example, melanoma clinic and GU oncology)

During this 3-year program, Fellows will be required to conduct a research project and basic, translational or clinical research in their areas of specialization with Holden Cancer Center Investigators.

Fellow will have the opportunity to participate in the ICTS Certificate Program or selected coursework in clinical investigation.

Fellows will be encouraged to apply for peer-reviewed funding (including ASCO YIA) and apply to society-based clinical investigator workshops (ASH, ASCO, LLS, LRF).  Fellows will also attend and will be encouraged to present at national meetings focused on their area of subspecialization.

Links

Clinical Educator Pathway

This track prepares the fellow for an academic career in medical education, with formal training and a certificate offered through our Office of Consultation and Research in Medical Education. In addition to formal study, fellows in this pathway will develop an educational portfolio and work with a faculty member to develop a new curriculum project.

Physician Scientist Pathway

This track prepares the fellow for an academic career focused on basic and/or translational laboratory research. This pathway integrates fellowship training to prepare for board certification with research training. Research mentors may be a member of the division, but can be investigators in other divisions of Internal Medicine or other departments of the University of Iowa (for example, the Interdisciplinary Immunology Program, Pharmacology, or Biochemistry), depending on the fellow’s research interests

Advanced Hematology Pathway

The goal of the Advanced Hematology pathway is to prepare the fellow for a career in academia with a focus on benign or malignant hematology.  This curriculum track will prepare the fellow for an academic career as a subspecialist without the need for additional subspecialty training post hematology/oncology fellowship.

The University of Iowa is well poised to offer training and both benign and malignant hematology.  The University of Iowa Hematology T32 training grant is an NIH funded training program in hematology that has been very successful in training young scientist and physician scientist for academic careers for over 40 years at the University of Iowa. 

Fellows in the Advanced Hematology track would participate in the T32 curriculum which includes core lectures in clinical hematology and workshops in hematology research methods along with training in grant writing.  Fellows would have a mentoring committee and develop individual development plans.  The foundation of training in this track is centered on an individual mentored research project, marked by a period of intensive, sustained research under the guidance of an established, dedicated mentor. 

Fellows specializing in benign hematology will have additional benign hematology clinics in their second and third year as well as additional rotations in hematopathology and molecular pathology.

The fellow may choose to specialize in malignant hematology.  Our Bone Marrow Transplant service is well-established active service performing auto and allo-transplants. In 2019 our Stem Cell Transplant and Cellular Therapy program moved to a new unit with additional beds. We also have a burgeoning CAR-T cell therapy program which provides cutting edge therapy to patients with blood disorders.

The fellow specializing in malignant hematology would have an intensive clinical training experience that would meet the eligibility requirements for FACT accreditation (Foundation for the Accreditation of Cellular Therapy).  Upon completion of the program, the fellow would immediately be eligible to attend in a transplant program without an additional 1-year fellowship.

Fellows as Clinician Educators (FACE)

The Fellows as Clinician Educators (FACE) Program is designed to introduce future clinician-educators to a set of skills which may be of use in their career. The program presents concepts of educational design and research, lecture development, evaluation, observation and feedback. At the conclusion of the program, FACE participants are required to develop a teaching portfolio.

Learn more about FACE

Learn More

Holden Comprehensive Cancer Center

Visit the HCCC website

Learn about Holden (video)

The facilities at Holden

The HCCC NCI designation (video)

Video tour of the new BMT/Cellular Therapy unit:


Graduate Medical Edducation at Iowa

How to Apply

Applications are only accepted through the Electronic Residency Application System(ERAS).

US residents should contact their Dean's Office or ERAS at https://students-residents.aamc.org/training-residency-fellowship/applying-fellowships-eras/.

International residents should contact the ECFMG at http://www.ecfmg.org/eras/index.html.

H1B and J1 visas accepted.

An ECFMG certificate must accompany the ERAS application.

A complete ERAS application includes:

  • Personal statement
  • Four letters of support (generally to include letters from the office of the dean of the college of medicine from which applicant graduated, as well as from program director and/or department head from Internal Medicine residency program)
  • Copies of your transcripts for USMLE Steps 1, 2, and 3 must accompany application

The deadline for applications is September 30.
Selected candidates will be invited to interview.

If you have any questions, contact the program at hemoncfellowship@uiowa.edu.

Life doesn't stop when you are in training!
PDF iconClick here

Board Certification

Medical specialty certification in the United States is a voluntary process which serves multiple purposes for the trainee and the public.

Certification is

  • one mission of the training program to produce trainees who meet board eligibility criteria;
  • distinguishes a physician as someone with a distinct level of expertise;
  • provides more opportunities when applying for employment;
  • presents resources and tools by the ABMS;
  • a commitment to life-long improvement for providing the best patient care; and
  • elevates physicians into the ranks of doctors committed to the highest standards of healthcare.

For more information visit the American Board of Internal Medicine for specifics on board certification requirements.

Eligibility Criteria

Qualified applicants to the University of Iowa Hematology and Oncology Fellowship Program are those who have successfully completed medical school and a medicine residency program at an accredited institution.

Interview Information

We will interview selected candidates beginning in September through October. Because of COVID-19, our interview process will be virtual. Once scheduled, your interview itinerary will also include a link to our "Welcome Presentation," which will give you an overview of the program. 

On your interview day, you will have the opportunity to meet the program director and associate program director as well as multiple faculty members. Based on information you provide in your application, we will strive to match you with the faculty interviewers in your field of interest. We will also arrange a session for you with our current fellows who can describe life in Hematology/Oncology at the University of Iowa as well as life in Iowa City.

We realize that selecting a fellowship “virtually” is a challenge. In addition to our interviews and fellow panels, we will also soon supplement the already-robust information about our program on these webpages with even more information about our program. For now we invite you to learn more about graduate medical education at University of Iowa Health Care, the University of Iowa, and Iowa City!

Our People

Program Leadership

Daniel Berg, MD
Director, Hematology-Oncology Fellowship Program
Associate Professor of Internal Medicine

Phone: 319-353-7800
Email: hemoncfellowship@uiowa.edu


 

Usha Perepu, MBBS
Associate Director, Hematology-Oncology Fellowship Program
Assistant Professor of Internal Medicine


 

Mohammed Milhem, MBBS
Clinical Professor and Director
Division of Hematology, Oncology and Blood & Marrow Transplantation

Faculty

Taher Abu Hejleh, MBBS
Clinical Associate Professor
Area of Specialty/Research: Thoracic oncology


Arwa Aburizik, MD, MS
Clinical Assistant Professor
Area of Specialty/Research: Psychiatry and oncology


Sabarish Ayyappan, MD
Clinical Assistant Professor
Area of Specialty/Research: Lymphoma


Daniel Berg, MD
Associate Professor
Area of Specialty/Research: Gastrointestinal oncology; Medical education


Thomas Carter, MD, PhD
Emeritus Associate Professor
Area of Specialty/Research: Leukemia


Chandrikha Chandrasekharan, MBBS
Clinical Assistant Professor
Area of Specialty/Research: Neuroendocrine carcinoma


Shobha Chitneni, MD
Clinical Assistant Professor
Area of Specialty/Research: Community oncology


Gerald Clamon, MD
Professor
Area of Specialty/Research: Thoracic oncology


Jad El Masri, MD
Clinical Assistant Professor


Umar Farooq, MD
Clinical Assistant Professor
Area of Specialty/Research: Lymphoma


Muhammad Furqan, MD
Clinical Assistant Professor
Area of Specialty/Research: Thoracic oncology


Rohan Garje, MBBS
Clinical Assistant Professor
Area of Specialty/Research: Genitourinary oncology


Asad Javed, MBBS
Clinical Assistant Professor
Area of Psecialty/Research: Melanoma, HCC


Mark Karwal, MD
Clinical Associate Professor
Area of Specialty/Research: Breast cancer, Hepatocellular carcinoma


Douglas Laux, MD
Clinical Assistant Professor
Area of Specialty/Research: Head and neck cancer


Steven Lentz, MD, PhD
Professor
Area of Specialty/Research: Clotting disorders


Brian Link, MD
Professor
Area of Specialty/Research: Lymphoma


Donald Macfarlane, MD, PhD
Professor
Area of Specialty/Research: Benign hematology


Margarida Magalhaes-Silverman, MD
Clinical Professor
Area of Specialty/Research: BMT


Eric Mou, MD
Clinical Assistant Professor


Mohammed Milhem, MBBS
Clinical Professor and Chief, Section of Oncology
Area of Specialty/Research: Melanoma and Sarcoma; Clinical trials; Immunotherapy


Varun Monga, MD
Clinical Associate Professor
Area of Specialty/Research: Neuro-oncology


Usha Perepu, MBBS, MRCP
Assistant Professor
Area of Specialty/Research: Benign hematology


Sneha Phadke, DO
Clinical Assistant Professor
Area of Specialty/Research: Breast cancer


Dhivya Prabhakar, MBBS
Clinical Assistant Professor
Area of Specialty/Research: Thoracic oncology


Susan Roeder, DO, MS
Clinical Associate Professor
Area of Specialty/Research: Breast oncology


Saima Sharif, MD, MS
Clinical Associate Professor
Area of Specialty/Research: Colorectal cancer


Christopher Strouse, MD
Clinical Assistant Professor
Area of Specialty/Research: Hematologic malignancy


Grerk Sutamtewagul, MD
Clinical Assistant Professor
Area of Specialty/Research: Lymphoma, benign hematology


Mario Sy, MD
Clinical Assistant Professor
Area of Specialty/Research: Community oncology


Michael Tomasson, MD
Professor
Area of Specialty/Research: BMT, multiple myeloma


Praveen Vikas, MBBS
Clinical Assistant Professor
Area of Specialty/Research: Breast cancer


George Weiner, MD
Professor
Area of Specialty/Research: Lymphoma
The Weiner Translational Research Lab


Yousef Zakharia, MD
Clinical Assistant Professor
Area of Specialty/Research: GU oncology, clinical trials


William Zeitler, MD, MPH
Associate
Area of Specialty/Research: Thoracic oncology, Medical education


Research Faculty

Anil Chauhan, MTech, PhD
Associate Professor
The Chauhan lab


Sanjana Dayal, PHD
Associate Professor
Sanjana Dayal lab


Nirav Dhanesha, PhD
Research Assistant Professor


Rebecca Dodd, PhD
Assistant Professor
The Dodd lab


Prakash Doddapattar, PhD
Research Assistant Profesor


Manasa K. Nayak, PhD
Research Assistant Professor


William Thiel, PhD
Research Assistant Professor
The Thiel lab

Current Fellows

First Year Fellows

Raafat Alameddine

 

Raafat Alameddine, MD
Medical School: merican University of Beirut
Residency: Case Western Reserve University


Dean Elhag

 

Dean Elhag, MD
Medical School: University of Iowa
Residency: University of Iowa


John Rieth

 

John Rieth, MD
Medical School: Indiana University
Residency: University of Iowa


Alex Sieg

 

Alex Sieg, MD
Medical School: Indiana University
Residency: University of Iowa


Second Year Fellows

 

Laila Babar, MBBS
Medical School: Aga Khan University
Residency: Allegheny Health Network


 

Austin Greco, MD
Medical School: University of Iowa
Residency: University of Iowa


 

Kit Poonsombudlert, MD
Medical School: Faculty of Medicine Vajira Hospital
Residency: University of Hawaii


 

Alex Tungesvik, MD
Medical School: University of Missouri-Columbia
Residency: University of South Florida


Third Year Fellows

 

Adithya Chennamadhavuni, MBBS
Medical School: Osmania Medical College
Residency: Gunderson Health System


 

Gudbjorg Jonsdottir, MD
Medical School: University of Iceland Faculty of Medicine
Residency: University of Iowa


 

Jennifer Keiser, MD
Medical School: University of Illinois College of Medicine
Residency: University of Illinois at Chicago


Travis Snyders

 

Travis Snyders, MD
Medical School: University of Iowa
Residency: University of Iowa

Recent Graduates

2021

Josiah An, community oncology, Winston-Salem, North Carolina
Justin Chau, University of Iowa Hospitals and Clinics
Seth Maliske, community oncology, Bismarck, North Dakota
Nanmeng Yu, University of Iowa Hospitals and Clinics

2020

Isaac Chambers, private practice, Hays, Kansas
Jad el Masri, University of Iowa, Quad Cities clinic, Bettendorf, Iowa
Susan Slycord, private practice, Cedar Rapids, Iowa
Chris Strouse, University of Iowa Hospitals and Clinics

2019

Umang Swami, MBBS, Huntsman Cancer Institute, University of Utah
William Zeitler, MD, University of Iowa Hospitals and Clinics
Najla Itani, MD, Community Oncology, Myrtle Beach, South Carolina
Muhammad Saqlain, MBBS, BMG Hematology and Medical Oncology, South Bend, Indiana

2018

Vyshak Alva Venur, MBBS, Fred Hutchinson Cancer Institute, University of Washington
Andrew Iliff, MD, Missouri Cancer Associates, Columbia, Missouri
Kalyan Nadiminti, MD, University of Wisconsin, Madison, Wisconsin
Meredith Schaffner, MD, Oregon Health Sciences University, Portland, Oregon

2017

Grerk Sutamtewagul, MD, University of Iowa Hospitals and Clinics
Ravi Patel, MD, Texas Oncology, Richmond, Texas
Rohan Garje, MD, University of Iowa Hospitals and Clinics
Varun Monga, MD, University of Iowa Hospitals and Clinics

2016

Sneha Phadke, DO, University of Iowa Hospitals and Clinics
Rachna Raman, MD, Bon Secours Cancer Institute, Richmond, Virginia
Zhaohui Jin, MD, Mayo Clinic, Rochester, Minnesota
Chinemerem Abanonu, MD, Maryland Parkway Oncology/Hematology, Las Vegas, Nevada

Chair, Department of Internal Medicine

Isabella Grumbach, MD, PhD
Interim Chair and DEO, Department of Internal Medicine
Kate Daum Endowed Professor
Professor of Medicine – Cardiovascular Medicine
Professor of Radiation Oncology

Life in Iowa as a Hem/Onc Fellow

It’s not all work! 

Every summer we have a picnic which is a great way to get to know your colleagues in an informal setting.
[view photos]


Our fellows attended the latest Iowa Oncology Society meeting.
[view photo]


Every year we host the Iowa Night reception at the annual ASCO meeting.  This is an enjoyable evening that allows us to meet up with our former fellows and others who have connections to Iowa.
[view photos]


At the end of the year we have our annual Graduation Dinner to honor our graduating fellows.
[view photos]

Summer Picnic Photos

Iowa Oncology Society Meeting

ASCO Iowa Night Photos

Graduation Dinner Photos

Connections Newsletter

Connections is our fellowship newsletter. This helps us stay connected with our former fellows after they have graduated and gone out into the world. It also helps us keep our graduates informed about what’s going on in the Division of Hematology, Oncology, and Blood & Marrow Transplantation at the University of Iowa.

Current Issue

Past Issues

Giving

You can help make a difference by giving to the Hematology & Medical Oncology Fellowship Program!

Your financial support helps fund educational training and innovations and also provides unrestricted resources that can be used when and where the need is the greatest.

Make an online gift to the Fellowship Program